Business
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
- TRYNGOLZA® generated $108 million in net product sales in 2025, the first year of launch – - Olezarsen sHTG launch preparations on track, sNDA submitted -
About this update from Ionis Pharmaceuticals, Inc.
[{"type":"text","content":"\n- TRYNGOLZA® generated $108 million in net product sales in 2025, the first year of launch –\n\n\n- Olezarsen sHTG launch preparations on track, sNDA submitted -\n\n\n- Exceeded 2025 financial guidance, 2026 guidance reflects commitment to independently deliver a steady cadence of innovative medicines to patients -\n\n\n CARLSBAD, Calif.--(BUSINESS WIRE)--\nIonis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the fourth quarter and year ended December 31, 2025.\n\n\n\"2025 was a defining year for Ionis, marked by the successful execution of our first two independent launches and multiple positive data readouts across our pipeline, positioning Ionis for continued success in 2026,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “This year, we are poised for two additional independent launches of groundbreaking therapies — olezarsen for severe hypertriglyceridemia, our first launch in a broad patient population, and zilganersen for Alexander disease, our first launch from our leading neurology pipeline. Our partnered pipeline is also on track for multiple groundbreaking Phase 3 readouts, beginning with the recent positive data for bepirovirsen in chronic hepatitis B to be followed by two cardiovascular outcome trials — the pelacarsen Lp(a) HORIZON trial mid-year 2026 and the eplontersen CARDIO-TTRansform trial in the second half of 2026. Together, this progress positions Ionis to continue delivering a steady cadence of transformative medicines to people living with serious diseases, fueling substantial growth and long-term value creation.\"\n\n\nFourth Quarter and Full Year 2025 Summary Financial Results(1):\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nThree months ended\n\n\n\n\n\n\n \n\n\n\n\n\n\nYear ended\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nDecember 31,\n\n\n\n\n\n\n \n\n\n\n\n\n\nDecember 31,\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n2025\n\n\n\n\n\n\n \n\n\n\n\n\n\n2024\n\n\n\n\n\n\n \n\n\n\n\n\n\n2025\n\n\n\n\n\n\n \n\n\n\n\n\n\n2024\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n(amounts in millions)\n\n\n\n\n\n\n\n\nTotal revenue\n\n\n\n\n\n\n \n\n\n\n\n\n\n$203\n\n\n\n\n\n\n \n\n\n\n\n\n\n$227\n\n\n\n\n\n\n \n\n\n\n\n\n\n$944\n\n\n\n\n\n\n \n\n\n\n\n\n\n$705\n\n\n\n\n\n\n\n\nOperating expenses\n\n\n\n\n\n\n \n\n\n\n\n\n\n$418\n\...